연속 혈당 모니터링 시스템 시장 : 제품, 구성요소, 검사 부위, 환자 치료 환경, 용도별 - 세계 예측(2025-2030년)

The Continuous Blood Glucose Monitoring Systems Market was valued at USD 4.50 billion in 2023, expected to reach USD 4.86 billion in 2024, and is projected to grow at a CAGR of 8.14%, to USD 7.79 billion by 2030.

Continuous Blood Glucose Monitoring Systems (CGMS) are dynamic, minimally invasive technologies designed to provide real-time glucose level assessments, primarily for diabetic patients. The necessity for CGMS arises from the growing global diabetes prevalence and the urgent need for better glycemic control to reduce associated health complications. Its applications extend beyond diabetic patients to include athletes and other health-conscious individuals seeking optimal glucose management. End-use sectors include hospitals, clinics, and homecare settings, facilitating both professional and personal health monitoring. Market growth is driven by technological advancements, heightened awareness regarding diabetes management, and rising health expenditures. Key influencing factors include an aging population and increased disposable incomes, particularly in developing regions embedding adaptive health solutions. Recent trends unveiling wearable technology innovations offer significant market opportunities. Companies pursuing collaborations for tech upgrades and data integration can leverage these opportunities effectively. However, limitations such as high costs, varying reimbursement policies, and the complexity of regulatory clearances hinder growth. Emerging markets face challenges like limited healthcare infrastructure and awareness. Innovation should focus on enhancing user ease, accuracy, and integrating AI analytics to offer predictive insights, as well as wireless and non-invasive monitoring methods. Research avenues, particularly in improving sensor longevity and reducing size, will likely lead to business expansion. This market is dynamic, highly competitive, and poised for transformative growth, driven by an urgent demand for personalized health monitoring. Companies need to invest in R&D, align with regulatory standards, and focus on strategic partnerships to harness market potential. Emphasizing education campaigns, optimizing cost structures, and expanding low-cost device availability will further mitigate current barriers and bolster market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Continuous Blood Glucose Monitoring Systems Market

The Continuous Blood Glucose Monitoring Systems Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Need an effective way to detect drastic changes in blood glucose for increasing diabetes cases
  • Benefits associated with continuous blood glucose monitoring systems over Point-of-Care glucometers
  • Increasing awareness through government initiatives for the product
• Market Restraints
  • Accuracy and precision on measurement and cost associated with sensor lifetime
• Market Opportunities
  • Growing adoption rate of continuous blood glucose monitoring systems in home healthcare
  • Potential undiagnosed patient population
• Market Challenges
  • Instability of patterns and reproducibility to results

Porter's Five Forces: A Strategic Tool for Navigating the Continuous Blood Glucose Monitoring Systems Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Continuous Blood Glucose Monitoring Systems Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Continuous Blood Glucose Monitoring Systems Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Continuous Blood Glucose Monitoring Systems Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Continuous Blood Glucose Monitoring Systems Market

A detailed market share analysis in the Continuous Blood Glucose Monitoring Systems Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Continuous Blood Glucose Monitoring Systems Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Continuous Blood Glucose Monitoring Systems Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Continuous Blood Glucose Monitoring Systems Market

A strategic analysis of the Continuous Blood Glucose Monitoring Systems Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Continuous Blood Glucose Monitoring Systems Market, highlighting leading vendors and their innovative profiles. These include A. Menarini Diagnostics s.r.l., Abbott Laboratories, B. Braun Melsungen AG, Dexcom, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlySens Incorporated, Johnson & Johnson Services, Inc., LifeScan IP Holdings, LLC, Medtronic PLC, Novo Nordisk A/S, OrSense Ltd., PHC Holdings Corporation, Senseonics Holdings, Inc., and Tandem Diabetes Care, Inc..

Market Segmentation & Coverage

This research report categorizes the Continuous Blood Glucose Monitoring Systems Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Continuous Glucose Monitoring Systems and Self-Monitoring Blood Glucose Systems. The Continuous Glucose Monitoring Systems is further studied across Receivers, Sensors, and Transmitters. The Self-Monitoring Blood Glucose Systems is further studied across Blood Glucose Meters, Lancets & Lancing Devices, and Testing strips.
• Based on Component, market is studied across CGM Monitor, CGM Transmitter, and Glucose Sensor.
• Based on Testing Site, market is studied across Alternate Site Testing and Fingertip Testing.
• Based on Patient Care Setting, market is studied across Hospital & Clinics and Self or Home Care.
• Based on Application, market is studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Need an effective way to detect drastic changes in blood glucose for increasing diabetes cases
    • 5.1.1.2. Benefits associated with continuous blood glucose monitoring systems over Point-of-Care glucometers
    • 5.1.1.3. Increasing awareness through government initiatives for the product
  • 5.1.2. Restraints
    • 5.1.2.1. Accuracy and precision on measurement and cost associated with sensor lifetime
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing adoption rate of continuous blood glucose monitoring systems in home healthcare
    • 5.1.3.2. Potential undiagnosed patient population
  • 5.1.4. Challenges
    • 5.1.4.1. Instability of patterns and reproducibility to results
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Continuous Blood Glucose Monitoring Systems Market, by Product

• 6.1. Introduction
• 6.2. Continuous Glucose Monitoring Systems
  • 6.2.1. Receivers
  • 6.2.2. Sensors
  • 6.2.3. Transmitters
• 6.3. Self-Monitoring Blood Glucose Systems
  • 6.3.1. Blood Glucose Meters
  • 6.3.2. Lancets & Lancing Devices
  • 6.3.3. Testing strips

7. Continuous Blood Glucose Monitoring Systems Market, by Component

• 7.1. Introduction
• 7.2. CGM Monitor
• 7.3. CGM Transmitter
• 7.4. Glucose Sensor

8. Continuous Blood Glucose Monitoring Systems Market, by Testing Site

• 8.1. Introduction
• 8.2. Alternate Site Testing
• 8.3. Fingertip Testing

9. Continuous Blood Glucose Monitoring Systems Market, by Patient Care Setting

• 9.1. Introduction
• 9.2. Hospital & Clinics
• 9.3. Self or Home Care

10. Continuous Blood Glucose Monitoring Systems Market, by Application

• 10.1. Introduction
• 10.2. Gestational Diabetes
• 10.3. Type 1 Diabetes
• 10.4. Type 2 Diabetes

11. Americas Continuous Blood Glucose Monitoring Systems Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Continuous Blood Glucose Monitoring Systems Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Continuous Blood Glucose Monitoring Systems Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. A. Menarini Diagnostics s.r.l.
• 2. Abbott Laboratories
• 3. B. Braun Melsungen AG
• 4. Dexcom, Inc.
• 5. Eli Lilly and Company
• 6. F. Hoffmann-La Roche AG
• 7. GlySens Incorporated
• 8. Johnson & Johnson Services, Inc.
• 9. LifeScan IP Holdings, LLC
• 10. Medtronic PLC
• 11. Novo Nordisk A/S
• 12. OrSense Ltd.
• 13. PHC Holdings Corporation
• 14. Senseonics Holdings, Inc.
• 15. Tandem Diabetes Care, Inc.